Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement
- PMID: 27440714
- DOI: 10.1160/TH16-05-0349
Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement
Abstract
The serum TXB2 (sTXB2) assay reflects the pharmacodynamics of platelet inhibition by low-dose aspirin. However, different studies reported variable sTXB2 values. sTXB2 assay requires whole blood incubation at 37 °C as a condition for optimal thrombin generation, arachidonic acid release and its metabolism by platelet cyclooxygenase-1 to form TXA2. Access to 37 °C incubation may be variably delayed, and different methods to quantitate sTXB2 may contribute to variable results between different Centers. We investigated whether delaying 37 °C incubation and/or analytical issues affect sTXB2 concentrations, biasing the assessment of aspirin responsiveness. Sixty-eight samples from 54 volunteers, on- and off-aspirin, were incubated at 37 °C immediately after sampling (reference sample) or after 5, 10, 15, 20, 30 or 60 minutes at room temperature (RT); 8 samples remained at RT 60 minutes, without subsequent incubation; 314 sera were measured by enzyme immunoassay (EIA) and liquid chromatography-tandem mass-spectrometry (LC/MS-MS) methods. sTXB2 concentrations decreased exponentially as a function of the delay before 37 °C incubation, ranging from 94 ± 11 % at 5 minutes to 23 ± 22 % of the reference sample after 60 minutes at RT. There was high agreement between EIA and LC/MS-MS. Moreover, we simulated the influence of a 15- or 30-minute delayed incubation on 300 sTXB2 measurements from previously-studied, aspirin-treated patients. Delayed incubation reduced the percentage of aspirin 'non-responders' by 22 % to 52 %, depending on the response threshold. In conclusion, a variable delay in the 37 °C incubation of blood samples may affect the assessment of platelet cyclooxygenase-1 inhibition by aspirin and confound the characterization of the determinants of aspirin responsiveness.
Keywords: Thromboxane B2; aspirin; cyclooxygenase-1; enzyme immunoassay; liquid chromatography-tandem mass spectrometry.
Similar articles
-
Suboptimal inhibition of platelet cyclooxygenase 1 by aspirin in systemic lupus erythematosus: association with metabolic syndrome.Arthritis Care Res (Hoboken). 2014 Feb;66(2):285-92. doi: 10.1002/acr.22169. Arthritis Care Res (Hoboken). 2014. PMID: 24022862 Free PMC article. Clinical Trial.
-
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease.Clin Pharmacol Ther. 2006 Aug;80(2):115-25. doi: 10.1016/j.clpt.2006.04.011. Epub 2006 Jul 3. Clin Pharmacol Ther. 2006. PMID: 16890573 Clinical Trial.
-
Aspirin response: Differences in serum thromboxane B2 levels between clinical studies.Platelets. 2016;27(3):196-202. doi: 10.3109/09537104.2015.1072147. Epub 2015 Aug 13. Platelets. 2016. PMID: 26270593
-
Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.Circulation. 2004 Mar 30;109(12):1468-71. doi: 10.1161/01.CIR.0000124715.27937.78. Epub 2004 Mar 22. Circulation. 2004. PMID: 15037526 Clinical Trial.
-
A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.J Clin Pharmacol. 2000 Dec;40(12 Pt 2):1509-15. J Clin Pharmacol. 2000. PMID: 11185674 Clinical Trial.
Cited by
-
Measurement of Thromboxane Biosynthesis in Health and Disease.Front Pharmacol. 2019 Oct 30;10:1244. doi: 10.3389/fphar.2019.01244. eCollection 2019. Front Pharmacol. 2019. PMID: 31736753 Free PMC article. Review.
-
Stability of the thromboxane B2 biomarker of low-dose aspirin pharmacodynamics in human whole blood and in long-term stored serum samples.Res Pract Thromb Haemost. 2024 Nov 12;8(8):102623. doi: 10.1016/j.rpth.2024.102623. eCollection 2024 Nov. Res Pract Thromb Haemost. 2024. PMID: 39698184 Free PMC article.
-
Once- versus Twice-Daily Aspirin in Patients at High Risk of Thrombotic Events: Systematic Review and Meta-Analysis.Am J Cardiovasc Drugs. 2021 Jan;21(1):63-71. doi: 10.1007/s40256-020-00409-x. Am J Cardiovasc Drugs. 2021. PMID: 32394295
-
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia.Clin Pharmacol Ther. 2022 Apr;111(4):939-949. doi: 10.1002/cpt.2485. Epub 2021 Nov 20. Clin Pharmacol Ther. 2022. PMID: 34743317 Free PMC article.
-
Precision antiplatelet therapy.Res Pract Thromb Haemost. 2023 Mar 28;7(3):100138. doi: 10.1016/j.rpth.2023.100138. eCollection 2023 Mar. Res Pract Thromb Haemost. 2023. PMID: 37215094 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources